01:29 PM EDT, 03/23/2026 (MT Newswires) -- WeRide (WRD) reported on Monday a narrower net loss in Q4 as revenue jumped from a year ago.

Shares advanced 6.6% as intraday trading volume rose to over 13.7 million from a daily average of roughly 3.97 million.

Insmed ( INSM ) said a phase 3b study of Arikayce, as part of a multidrug regimen to treat patients with Mycobacterium avium complex lung infection, who have not started antibiotics, has met its primary and secondary endpoints.

Shares rose 4%, with intraday trading volume of more than 2.01 million against a daily average of about 2.38 million.

Wolfe Research upgraded Celldex Therapeutics ( CLDX ) to outperform from peer perform.

Shares rose 3.5% as intraday trading volume increased to over 902,000 from a daily average of about 847,000.

Price: 31.94, Change: +1.04, Percent Change: +3.37